References
Ahmed I.A.B. (2024) A comprehensive review on weight gain following discontinuation of glucagon‑like peptide‑1 receptor agonists for obesity. Journal of Obesity, 2024(1), 8056440.
Ara R., Wailoo A.J. (2011) NICE DSU Technical Support Document 12: The use of health state utility values in decision models.
Boddeti S., Noor K., Ansar M., Abera M., Suresh S.B., Malireddi A., Khan S. (2025) Impact of obesity on in vitro fertilization (IVF) outcomes: a systematic review. Cureus, 17(8), e90695.
Cherney D.Z., Belmar N., Bjornstad P., Chacko M.M., Gunnarsson T.P., Hodgin J.B., Kretzler M., Pruijm M., Schytz P.A., Tuttle K.R. (2025) Rationale, design and baseline characteristics of REMODEL, a mechanism‑of‑action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation.
Coulman K.D., Hopkins J., Brookes S.T., Chalmers K.A., Main B.G., Owen‑Smith A., Hughes R., Blazeby J.M. (2016) A core outcome set for the benefits and adverse events of bariatric and metabolic surgery: the BARIACT study. PLoS Medicine, 13(11), e1002187.
Dawson L.P., Carrington M.J., Haregu T., Nanayakkara S., Jennings G., Dart A., Stub D., Kaye D. (2023) Differences in predictors of incident heart failure according to atherosclerotic cardiovascular disease status. ESC Heart Failure, 10(6), 3398–3409.
Drummond M.F., Tarricone R., Torbica A. (2018) Economic evaluation of medical devices.
Ghanem O.M., Pita A., Nazzal M., Johnson S., Diwan T., Obeid N.R., Croome K.P., Lim R., Quintini C., Whitson B.A., Burt H.A. (2024) Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients. Surgical Endoscopy, 38(8), 4138–4151.
Gorst S., Williamson P.R., Kirkham J.J. (2025) COMET Initiative study record: Core outcome set development.
Khunti K., Schnecke V., Haase C.L., Harder‑Lauridsen N.M., Rathor N., Sommer K., Morgen C.S. (2023) Weight change and risk of obesity‑related complications: a retrospective population‑based cohort study of a UK primary care database. Diabetes, Obesity and Metabolism, 25(9), 2669–2679.
Kirkham J.J., Gorst S., Altman D.G., Blazeby J., Clarke M., Devane D., Gargon E., Williamson P.R. (2017) Core Outcome Set‑STAndards for Development: The COS‑STAD recommendations. PLoS Medicine, 14(11), e1002447.
Koye D.N., Magliano D.J., Nelson R.G., Pavkov M.E. (2018) The global epidemiology of diabetes and kidney disease. Advances in Chronic Kidney Disease, 25(2), 121–132.
Krüger A., van Dijk K.W., van Heemst D., Noordam R. (2025) Long‑term body mass index trajectories and the risk of type 2 diabetes mellitus and atherosclerotic cardiovascular disease using healthcare data from UK Biobank participants. Atherosclerosis, 403, 119135.
Lam C.S.P., Rodriguez A., Aminian A., Ferrannini E., Heerspink H.J.L., Jastreboff A.M., Laffin L.J., Pandey A., Ray K.K., Ridker P.M., Sanyal A.J., Yki‑Jarvinen H., Mason D., Strzelecki M., Bartee A.K., Cui C., Hurt K., Linetzky B., Bunck M.C., Nissen S.E. (2025) Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‑MMO trial. Obesity.
Latimer, N. (2011) NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data.
Lee H.S., Lim H.I., Moon T.J., Lee S.Y., Lee J.H. (2024) Trajectories of atherosclerotic cardiovascular disease risk scores as a predictor for incident chronic kidney disease. BMC Nephrology, 25(1), 141.
Luah X.W., Holst‑Hansen T., Lübker C. (2024) The association between body mass index and health‑related quality of life in the 2017 and 2018 Health Survey for England data: a cross‑sectional observational analysis. Diabetes, Obesity & Metabolism, 26(6), 2318–2328.
Panchal K., Lawson C., Chandramouli C., Lam C., Khunti K., Zaccardi F. (2024) Diabetes and risk of heart failure in people with and without cardiovascular disease: systematic review and meta‑analysis. Diabetes Research and Clinical Practice, 207, 111054.
Pandey S., Pandey S., Maheshwari A., Bhattacharya S. (2010) The impact of female obesity on the outcome of fertility treatment. Journal of Human Reproductive Sciences, 3(2), 62–67.
Sattar N., Lee M.M.Y. (2025) Estimating direct tissue effects versus weight loss effects of incretin‑based drugs for obesity on various chronic conditions. The Lancet Diabetes & Endocrinology, 13(4), 347–354.
West S., Scragg J., Aveyard P., Oke J.L., Willis L., Haffner S.J.P., Knight H., Wang D., Morrow S., Heath L., Jebb S.A., Koutoukidis D.A. (2026) Weight regain after cessation of medication for weight management: systematic review and meta‑analysis. BMJ, 392, e085304.
Wu H., Yang W., Guo T., Cai X., Ji L. (2025) Trajectory of body weight after drug discontinuation in the treatment of anti‑obesity medications. BMC Medicine, 23(1), 398.
Zeng M., Chen S., Fan T., Yang H., Cao P., Wang Z., Zhang Y., Zhang Y., Hunter D., Yang Q., Ding C. (2023) Associations of childhood‑to‑adulthood body size trajectories and genetic susceptibility with the risks of osteoarthritis: a population‑based cohort study of UK Biobank data. The Lancet Global Health, 11, S2.
ISBN: 978-1-4731-9488-5